Rapamycin inhibits activator protein-1 but not nuclear factor-kappaB activity of mature bone marrow-derived dendritic cells.
Rapamycin (Rapa), a recently introduced immunosuppressive drug, appears to be effective in preventing acute allograft rejection episodes. Its effects on differentiation and maturation of dendritic cells (DCs) have been studied. In this report, we evaluated the effects of Rapa on the intracellular signal transduction pathways in mature DCs. The results showed that Rapa did not depress p65, p50, or IkappaBalpha expression. However, it dramatically reduced activator protein-1 activation. The fact that Rapa exerts a specific effect on activator protein-1 activity in mature DCs may contribute to its unique actions to prevent allograft rejection and induce immune tolerance.
Wang
G-Y
GY
Liver Transplantation Institution, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, China.
Chen
G-H
GH
Li
H
H
Huang
Y
Y
Zhang
J
J
Jiang
N
N
Chen
W-J
WJ
D000199:Actins / Q000235:genetics; D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology* / Q000187:drug effects; D002467:Cell Nucleus / Q000187:drug effects / Q000502:physiology; D003713:Dendritic Cells / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D016328:NF-kappa B / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D051381:Rats; D011917:Rats, Inbred Lew; D020133:Reverse Transcriptase Polymerase Chain Reaction; D020123:Sirolimus / Q000494:pharmacology*; D018808:Transcription Factor AP-1 / Q000187:drug effects* / Q000378:metabolism
D000199:Actins; D016328:NF-kappa B; D018808:Transcription Factor AP-1; D020123:Sirolimus